{"id":"pq-0-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemolysis in G6PD-deficient patients"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Methemoglobinemia"}]},"_chembl":{"chemblId":"CHEMBL139578","moleculeType":"Small molecule","molecularWeight":"313.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PQ (0.2) refers to a formulation of primaquine or a primaquine-like compound at 0.2 mg/kg dosing. It works by generating reactive oxygen species within parasitized cells, particularly targeting the dormant liver stage (hypnozoites) of relapsing malarias. This mechanism enables radical cure by preventing relapses that occur weeks to months after initial blood-stage infection.","oneSentence":"PQ is a primaquine analog that acts as an 8-aminoquinoline antimalarial targeting the hypnozoite stage of Plasmodium vivax and P. ovale parasites.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:29:45.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Radical cure of Plasmodium vivax malaria"},{"name":"Radical cure of Plasmodium ovale malaria"},{"name":"Prevention of malaria relapse"}]},"trialDetails":[{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT01838902","phase":"PHASE3","title":"Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-08","conditions":"Malaria","enrollment":467}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":177,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Primaquine"],"phase":"phase_3","status":"active","brandName":"PQ (0.2)","genericName":"PQ (0.2)","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PQ is a primaquine analog that acts as an 8-aminoquinoline antimalarial targeting the hypnozoite stage of Plasmodium vivax and P. ovale parasites. Used for Radical cure of Plasmodium vivax malaria, Radical cure of Plasmodium ovale malaria, Prevention of malaria relapse.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}